	TH AND HUMAN SERVICES G ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*
Rockville, MD 20857	FEINUMBER 3010453141
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	t.
Mr. Pramod Kumar Singh, Head of ()(4) Opera	tions - India and Africa
FIRM NAME	STREET ADDRESS
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ, Pharma Zone, Phase II, Sector III
CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED	
Pithampur, District Dhar, Madhya Pradesh, 454775 India	(b)(4) Drug Products Manufacturer

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED: FACILITY AND EQUIPMENT SYSTEM

OBSERVATION 1

Equipment and utensils are not cleaned at appropriate intervals to prevent that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically,

You failed to adequately clean and maintain your non-dedicated equipment used for drug products manufacturing. For example,

A. On 14-Jun-2024, I observed white to off-white	
Duct of	ID: ^{(b)(4)} located in Block ^{(b)(4)}
^{(b) (4)} while this equipment was in Type A c	leaning status. This non-dedicated ^{(b) (4)} is used in the
manufacturing of the following (b)(4) drug products	

a. mg ^{(b) (4)} n b. c.	1g (b) (4)	(b) (4) (b) (4	^{(b) (4)} Tablet Tablets ^(b) (4) mg ^{(b) (4)} mg ^{(b) (4)} Tablets ^{(b) (4)} mg ^{(b) (4)}	(б) (4)
SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Pratik S Upadhyay, Steven A Brettler,		Pretis 6 Locathyay Presis Signel By Pre a 6. Locathyay -6 Cate Soynet: 06-26-2004 X	DATE ISSUED
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL	OBSERVATIONS	PAGE 1 of 18 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*			
Rockville, MD 20857	FEI NUMBER			
NOCKVILLE, ID 2000,	3010453141			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED				
	ations - India and Africa			
FIRM NAME	STREET ADDRESS			
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,			
	Pharma Zone, Phase II, Sector III			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Pithampur, District Dhar, Madhya				
Pradesh, 454775 India				
Tiddeshi, 404775 India	<u> </u>			
d. (b)(4) Tab	lets $^{(b)(4)}$ mg $^{(b)(4)}$ mg $^{(b)(4)}$ mg $^{(b)(4)}$			
(b) (4)				
	(A) (A)			
On 17-Jun-2024. (b) (4) swab samples were collected from different locations of (b) (4) Duct of and analyzed by HPLC to identify the presence of drug substances of the previously				
manufactured drug products. Test data revealed the presence of drug substances of the above listed drug				
product indicating a potential for drug products cross-contamination that were manufactured using this				
^{(b) (4)} Swab test results are tabulated as follows:	oss-contamination that were manufactured using this			



(b) (4)

SEE REVERSE OF THIS PAGE			Pratit 8 Uposityay Investigation Bate Signed: 06-36-2004 X	DATE ISSUED 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIO	ONS	PAGE 2 of 18 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*			
Rockville, MD 20857	FEINUMBER 3010453141			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED				
Mr. Pramod Kumar Singh, Head of ()(4) Opera	tions - India and Africa			
FIRM NAME	STREET ADDRESS			
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,			
ur an	Pharma Zone, Phase II, Sector III			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Pithampur, District Dhar, Madhya Pradesh, 454775 India	(6)(4)Drug Products Manufacturer			
	6)(0)			

Furthermore, the swab samples testing showed numerous unknown peaks randomly eluting at different retention times in all ^{(b)(4)} swab samples tested by HPLC. These unknown peaks were not identified and accounted for in the above table. The highest result obtained for the unknown peaks was ^{(b)(4)} PPM. There is a potential for the swab test results to be even higher than the reported result in table 1 considering not the entire ^{(b)(4)} residues could be collected from the areas swabbed due to large quantity of ^{(b)(4)} residues that was present in the areas swabbed.

Upon becoming aware of the potential for carryover and cross-contamination issues based on swab samples test results on 18-Jun-2024, your firm reported no Field Alert to the agency within three (3) working days.

^{(b) (4)} PPM for **B.** Your firm considered acceptance limits of NMT NMT ^{(b) (4)} PPM for (b) (4) PPM for and NMT while reporting the swab sample test results (refer to Table 1). However, your minimum acceptance criteria as per the cleaning ^{(b) (4)} NMT ^{(b) (4)} PPM for ^{(b) (4)} and NMT ^{(b) (4)} PPM for (b) (4) Based on these validated acceptance limits, there is a potential for the carryover and cross-contamination of drug ^{(b) (4)} ID: ^{(b) (4)} Your Quality Unit provided no products manufactured using your non-dedicated justification for considering higher acceptance limits that undermines the obtained swab sample test results specifically for Furthermore, there is no procedure established for calculating equipment specific swab sample test result while your cleaning validation is based on equipment train (all equipment) that are used in the manufacturing of a given product that includes large number of equipment and the results calculated are based on total surface area of all equipment.

C. Your manual Type C (product changeover) equipment cleaning procedure is deficient. For example,

SEE REVERSE OF THIS PAGE			Pratis 5 Updahyay Prestigator Biged By Pre ta 6. Updahyay-6 Dis 5 for 06-36-3024 X	DATE ISSUED 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 3 of 18 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
12420 Parklat			DATE(S) OF INSPE	естіон 24-6/26/2024*	
Rockville, MI		-	FEI NUMBER	and the second of	
			3010453:	141	
Mr Pramod Ki		tions - In	ndia and	Africa	
FIRM NAME	Indi Singn, nead of the Opera	STREET ADDRESS	lluta anu	AIIICa	
	cories Limited	Pharma Zo	one, Pha:	. 11, 12, 13, se II, Sector	
CITY.STATE.ZIP CODE.COUNT Pithampur, Di Pradesh, 4547	istrict Dhar, Madhya	TYPE ESTABLISHME	INT INSPECTED	s Manufacturer	
^{(b) (4)} Add since their insta ^{(b) (4)}) was 2019. Per your (since their insta		f cleanlines m's hewest (b)(4) (b)(4) hav	(ID: b)(4 ve been cle	⁴⁾ of which the ol ^{(b) (4)}) was instal eaned in the	Duct performed ldest ^{(b) (4)} (ID: lled on 21-Jun- ^{(b) (4)} Duct areas
D. Standard Tes limited to:	st Procedures (STPs) used for swab	samples an	alyses are	deficient. For ex	ample, but not
clean drug subs the detection of STP refers to so Jun-2024, I obse solvent. The an 60% that also c completely into preparation. The much higher th unknown impur Subsequently, th No.: MVR-TLE detection of	onicating swab sample for erved ^(h) ml of ^{(h)(4)} was not suff nl of ^{(h)(4)} dipped only about 40 contained ^{(h)(4)} materials upon s the solution due to inadequacies i ere is a potential that the actual res an the reported results for ities than the reported results. here is no assurance over the reliabit CT-RD-013/00, Approval date: 25-N ^{(h)(4)} drug substance considering ure extraction of ^{(h)(4)} drug substance	(b) (4) Ef (b) (4) Ef assure the a (4) in test the ficient to dip (0% of swab swabbing from in your test sults for swal (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	P No.: IPP ffective da accuracy o ube contai p the entire o stick head om ^{(b)(4)} I procedure wab sample	PTLE013-02, Nar ate: 10-Feb-2014 of swab sample te ining (*)ml of e swab stick head d while the other ID: (************************************	established for est results. This (b)(4) On 17- l into approximately s not extracted ample solution potentially be Table 1) and idation (Report analysis for the etely into (b) (4) ml head.
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Pratik S Upadhyay, Investiga Steven A Brettler, Investiga			Pradit 5 Lipochiyay Investigator Bigenel By: Pra it 6 Libochiyay -6 Di 95-36 X	date issued 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	PECTIONAL O	BSERVATIO	INS	PAGE 4 of 18 PAGES

<i>50</i>	DEPARTMENT OF HEAD			
DISTRICT ADDRESS AND PHON 12420 Parklav Rockville, MI	wn Drive, Room 2032	JG ADMINISTRAT	TON DATE(S) OF INSPECTION 6/14/2024-6/26/2024 FEI NUMBER 3010453141	1*
FIRM NAME Mylan Laborat CITY, STATE, ZIP CODE, COUN	umar Singh, Head of (b)(4) Opera cories Limited	STREET ADDRESS (FDF-3) Pharma 2 TYPE ESTABLISHM	Plot Nos. 11, 12, 13 Zone, Phase II, Secto MENT INSPECTED	or III
Pithampur, D Pradesh, 454	istrict Dhar, Madhya 775 India	(W(4) Drug	g Products Manufactur	cer
21-Nov-2013 d swab sample fo Addition of ^(b) potential for inc not be a true ref 3. Your STP No assure the accur in test tube con about 60% of s	al ^{(b) (4)} indicated only about 60% complete extraction of ^{(b) (4)} m lection of the amount (PPM) of act co.: IPPNVP073-01, Name of Produces acy of swab sample test results. The	vab sample ng ml of 6 of swab h aterials into tives and im uct: nis STP refe ereby there ts obtained	ead could be dipped and the solution and the res purities present in the equ (*)(4) Effective date: 28-F rs to sonicating swab sam (*)(4) Addition of (*) is a potential for incomp will not be a true reflecti	(b)(4 thereby there is a ults obtained wil uipment swabbed Feb-2024 does no nple for (b)(4 ml indicated only olete extraction of
assure the accur ml test tube con- test tube is inad There is a potent solution is pract sample test resu- by using ^{(b)(4)} ml of test tube that solution due to		his STP ref and soni procedure d oill outside o ume of the t est your QC st tube. Eve I (IPPLAC3	icate for oes not take into conside (b)(4) + weigh of the test tube and as su test tube. This may lead t C Unit simulated swab tes n though they used highe 602-00), they were unabl	b samples into (b samples into (b)(4) eration that (^{(b)(4)}) int of a swab stick ich (^{(b)(4)}) of the co unreliable swal st sample solution er volume (^{(b)(4)}) ml e to (^{(b)(4)}) m
SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Pratik S Upadhyay, Investig Steven A Brettler, Investig		Press 6 Upachyay Iswedigatar Signed By: Pe is 8. Upachyay -6 Date Signer 65-55-2024 X 03 56.35	DATE ISSUED 6/26/2024

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

PAGE 5 of 18 PAGES

	EALTH AND HUMAN SERVICES DRUG ADMINISTRATION	
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION	
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*	
Rockville, MD 20857	FEI NUMBER 3010453141	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Mr. Pramod Kumar Singh, Head of (b) (4) Ope	erations - India and Africa	
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,	
	Pharma Zone, Phase II, Sector III	
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED	
Pithampur, District Dhar, Madhya Pradesh, 454775 India	(6)(4) Drug Products Manufacturer	

Based on the above listed inadequacies in your STPs and the practices of your QC Analysts while performing swab samples testing, there is a potential for getting unreliable test results on the lower side of the acceptance limits that may not trigger quality event (laboratory incident) leading to recleaning of the equipment upon investigation. Also, there is a potential for deficiencies in your analytical method cleaning validation leading to unreliable test results and carryover and/or cross-contamination risks among different drug products that are manufactured using non-dedicated equipment at your site.

E. Your Type A (batch to batch) equipment cleaning i	
000563943, Titled: Operation & cleaning of	^{(b) (4)} Model-
Version: 16.0, section 6.10.4 requires removing any	^{(b) (4)} that may be present from the machine with
the help of	^{(b)(4)} Further, the
must be removed from ^{(b)(4)} bowl by	^{(b) (4)} per section 6.10.5. Your
Production Operator stated the procedure was followe	d and ^{(b)(4)} residues were removed using ^{(b)(4)}
(b) (4) was used	to remove ^{(b)(4)} material from the equipment.
However, on 14-Jun-2024, I observed thick accumul	
areas for ^{(b)(4)} ID: ^{(b)(4)} while this equipment w	was in Type A clean status. This equipment was
awaiting to be used in the campaign manufacturin	g of product (6)(4)
$^{(6)}$ (4) Tablets $^{(6)}$ (4) mg	⁽⁴⁾ mg ^{(b)(4)} mg, batch number $^{(b)(4)}$

QUALITY SYSTEM

OBSERVATION 2

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

	EMPLOYEE(S)SIGNATURE Pratik S Upadhyay, Steven A Brettler,		Pratit 6 Upadhyay Boctaggir - a 8 8 Upadhyay - 6 Date Signet: 0F-3F-2004 X	date issued 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 6 of 18 PAGES

	TH AND HUMAN SERVICES GADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*
Rockville, MD 20857	FEINUMBER 3010453141
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Mr. Pramod Kumar Singh, Head of ()(4) Opera	tions - India and Africa
FIRM NAME	STREET ADDRESS
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ, Pharma Zone, Phase II, Sector III
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Pithampur, District Dhar, Madhya Pradesh, 454775 India	(6)(4) Drug Products Manufacturer

Specifically,

Your investigations of out-of-specification (OOS) results were inadequate because they lacked scientific rationale for root cause determinations. For example,

Tablets ^{(b)(4)} mg, and at 3 mon	Investigation PR ID: 3455440, Date Opened: 28-Mar-2024, Product: , Stability timepoint: Long Term (LT) (25°C/60%RH) at 18 months for ths for batch ^{(b)(4)} LT (25°C/60%RH), Issue: OOS/OOT result file test by HPLC, Final classification: Unconfirmed OOS, Specification ^{(b)(4)} Not less than ^(b) Table 2	s observed for
Batch. No. 25°C±2°C/60%	(b)(4) Stability Timepoint: 18 Month(s)/ (b)(4) (b)(4) (b)(4) (b)(4)	
Batch. No. 25°C±2°C/60%	^{(b) (4)} Stability Timepoint: 3 Month(s)/ (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)	
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Pratik S Upadhyay, Investigator Steven A Brettler, Investigator X	DATE ISSUED 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS	PAGE 7 of 18 PAGES


FOOD AND DRUG	TH AND HUMAN SERVICES 3 ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER 12420 Parklawn Drive, Room 2032	DATE(S) OF INSPECTION 6/14/2024-6/26/2024*
Rockville, MD 20857	FEI NUMBER
	3010453141
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	inal di dun di Yerizi tal
Mr. Pramod Kumar Singh, Head of (b)(4) Opera	tions - India and Africa STREET ADDRESS
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,
	Pharma Zone, Phase II, Sector III
CITY.STATE.ZIP CODE.COUNTRY Pithampur, District Dhar, Madhya	(0) (4) Drug Products Manufacturer
Pradesh, 454775 India	Brug Floduces Manufacturer
	(b) (4
Your OC Analyst aborted HPI C sample set seg	uence upon finding OOS and OOT dissolution test
results for batch numbers (b) (4) (OOS result)	
sequence, dissolution test samples of batches	(b)(4) (LT at 18 months), and (b)(4) (LT at 3
months) were not analyzed upon finding failing res	ults. The following issues were observed:
months) were not analyzed upon midning faming res	uns. The following issues were observed.
1. Test sample vials pertaining batches	^{(b)(4)} and ^{(b)(4)} were not injected into the HPLC
based on the OOS and OOT test results	0 × (N
justification provided for aborting sample	(h) (h)
	•
	nal test solutions and reperformed dissolution test for justification while the Phase 1 investigation revealed
no laboratory error.	Justification while the Phase 1 investigation revealed
	(manufacturing) investigations determined no root
	nducted under Phase 2B investigation, your Quality proper (6)(4) of (6)(4) in
Unit determined the root cause being im	
	ssolution test procedure number: INPNSD301-03,
Effective date: 03-Mar-2023 dissolution me	this (b)(4)
was followed by	
EMPLOYEE(S) SIGNATURE	DATE ISSUED
SEE REVERSE Pratik S Upadhyay, Investiga	
OF THIS PAGE Steven A Brettler, Investiga	ator Prats Subadyay meetadar a Luadyay-S Bues by Pack-2004
	X X
0.200	
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INS	PECTIONAL OBSERVATIONS PAGE 8 of 18 PAGES

	LTH AND HUMAN SERVICES JG ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
12420 Parklawn Drive, Room 2032 Rockville, MD 20857	6/14/2024-6/26/2024* FEINUMBER 3010453141
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Mr. Pramod Kumar Singh, Head of (b)(4) Opera	
Mylan Laboratories Limited	STREET ADDRESS (FDF-3) Plot Nos. 11, 12, 13, Indore SEZ, Pharma Zone, Phase II, Sector III
CITY.STATE.ZIP CODE.COUNTRY Pithampur, District Dhar, Madhya Pradesh, 454775 India	(0)(4) Drug Products Manufacturer
 dissolution media was prepared according root cause for this investigation to suggest if a suggest i	ive of the ^{(b)(4)} was ^{(b)(4)} properly in the dissolution he dissolution test solution preparation stated that the to the test procedure (INPNSD301-03). However, the improper ^{(b)(4)} of ^{(b)(4)} was not justified. 2B investigation, your Quality Unit disregarded the There was no reverification of dissolution media ^{(b)(4)} onducted to evaluate the impact of variations in ^{(b)(4)} on ablets ^{(b)(4)} mg. clude the root cause being improper ^{(b)(4)} of ^{(b)(4)} in of unit ^{(b)(4)} were within limits at ^{(b)(4)} tere within limits at ^{(b)(4)} dissolution time point for nit ^{(b)(4)} were within specification limit at ^{(b)(4)} Both the batches were tested using the same stock of a01-03) for ^{(b)(4)} Tablets is deficient. There on media that must be ^{(b)(4)} at ^(b) mepoints (refer to OBSERVATION 3B)
B. Laboratory Investigation PR ID: 3354171, Dat ^{(b)(4)} mg Capsules, Batch No.: ^{(b)(4)} Type observed for Assay, Result: ^{(b)(4)} %, OOT limit: NI	of Analyses: Assay by HPLC, Issue: OOT result was
re-dilution, re-stirring confirmed to the original (identified during the Phase 2A investigation. T	I no root causes and the results of re-injection, re-fill, OOT test result. There were no manufacturing issues he experimental studies performed under Phase 2B as with standard preparation. However, you performed
SEE REVERSE OF THIS PAGE Pratik S Upadhyay, Investig Steven A Brettler, Investig	
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE IN	SPECTIONAL OBSERVATIONS PAGE 9 of 18 PAGES

	ALTH AND HUMAN SERVICES RUG ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*
Rockville, MD 20857	FEINUMBER 3010453141
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Mr. Pramod Kumar Singh, Head of (b)(4) Ope:	rations - India and Africa
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,
	Pharma Zone, Phase II, Sector III
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Pithampur, District Dhar, Madhya Pradesh, 454775 India	()(4)Drug Products Manufacturer

retest analysis for Assay and Content Uniformity (CU) using new sample under Phase 2B investigation. I observed the following issues under Phase 2B investigation:

1. Upon obtaining the failing (OOS) test result for CU test for Unit ^(b)/₍₄₎ QC Analyst aborted the sample set sequence at Unit ^(b)/₍₄₎ due to HPLC column leakage.



The reinjected, re-fill, and re-diluted test results for Unit results. The results of Unit ⁽⁰⁾/₍₄₎ were observed ⁽⁰⁾⁽⁴⁾/₍₄₎% and ⁽⁰⁾⁽⁴⁾/₍₆₎% for re-injection and re-fill. Your firm initiated no separate laboratory incident to investigate the failing (OOS) results obtained for CU test. The OOS test results for CU test were invalidated stating instrument (HPLC ID: QCD571) error due to column leakage during this analysis. However, there was no message relating to column leakage was found in the Empower 3 audit trail for HPLC ID: QCD571.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Pratik S Upadhyay, Steven A Brettler,		Prait & Luestry Inscaling Signed St; Pra it & Lubadhyay-S Date Synet: 05-26-2024 X	date issued 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIO	NS	PAGE 10 of 18 PAGES

	ALTH AND HUMAN SERVICES
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*
Rockville, MD 20857	FEI NUMBER 3010453141
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Mr. Pramod Kumar Singh, Head of ()(4) Oper	
FIRM NAME	STREET ADDRESS
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,
n an - Martin and a share and a share a share a share a share a share and a share and a share and a share a sh	Pharma Zone, Phase II, Sector III
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Pithampur, District Dhar, Madhya Pradesh, 454775 India	(0)(4) Drug Products Manufacturer

2. There was no OOS investigation conducted to justify comparable results to the original result for Unit (4) during the original analysis and reinjection, re-fill, and re-diluted analyses while the results of (Unit (4) samples to Unit (4) were within specification limit.

3. There was no explanation provided for not reporting Unit (b)(4) tests results in the initial run and its correlation to OOS results obtained for Unit (4) in re-injection and re-fill. Furthermore, the chromatographic data of retest was not verified and signed by analytical QA.

4. Your Quality Unit conducted testing into compliance by retesting for the second time using new samples and changed HPLC equipment from HPLC ID: QCD571 to HPLC ID: QCD496. This retest analysis gave favorable (passing) results for CU and confirmed OOT result for Assay based on which your firm released the batch into the market.

C. Laboratory Investigation PR ID: 2970698, Date Opened: 19-Nov-2022, Product: Tablets ^{(b)(4)} mg, Batch No.: ^{(b)(4)} Type of Analyses: Dissolution by HPLC, Issue: ^{(b)(4)} timepoint for Unit ^(b) was ^(b) % against the acceptance criteria of ^{(b)(4)}% to ^(b) %. Result: Unit ^(b) not complying to ^(b) 4 stage criteria. Stage: Finished Product.

This OOS investigation was deficient to identify test method deficiencies. For example, dissolution test procedure (INPNSD301-03) for testing Tablets was deficient. There is no mention of the amount of dissolution media that must be 00(4) at dissolution timepoints (refer to OBSERVATION 3B).

D. Your procedure SOP-000463175, Titled: LABORATORY INVESTIGATION REPORT (LIR), Version: 12.0 pertaining to investigation of OOS, OOT, and atypical result(s) is deficient. There is no requirement in your current practices to charge confirmed OOT batch of finished product on the stability to monitor the batch throughout the shelf life of product to ensure the product would remain within the

SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Pratik S Upadhyay, Steven A Brettler,		Pretis 5 Usedhowy Investigator Bigned 5/ Pra 8 L Usedhowy-6 Date Symet 04-32-3204 X 03 45-36	DATE ISSUED 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIO	ONS	PAGE 11 of 18 PAGES

	LTH AND HUMAN SERVICES JG ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*
Rockville, MD 20857	FEINUMBER 3010453141
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Mr. Pramod Kumar Singh, Head of (b)(4) Opera	ations - India and Africa
	The state of the second s
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,
	Pharma Zone, Phase II, Sector III
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Pithampur, District Dhar, Madhya Pradesh, 454775 India	(6)(4) Drug Products Manufacturer

approved specification limit.

LABORATORY CONTROL SYSTEM

OBSERVATION 3

Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that components, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

A. Your standard test procedures (STPs) pertaining to testing of drug products and equipment cleaning swab samples of shared (non-dedicated) equipment are inadequate and it does not assure the reliability of the test data generated using these STPs. For examples,

1. Your equipment cleaning swab samples testing procedure STP No.: IPPTLE013-02, Name of Product: (b)(4) Effective date: 10-Feb-2014 established for the detection of (b)(4) drug substance is not in line with your analytical method validation (AMV) (Report No.: MVR-TLET-RD-013/00, Approval date: 25-Nov-2009) for the referenced STP No.: IPPTLE013-02. Per this procedure, injection volume for swab sample test solution, system suitability standard solutions, swab blank, and bracketing standard injections into HPLC is (4) μ l as injection volume. Thereby, it appeared that your firm has been deviating for over a decade while conducting swab samples analyses that is in deviation of your analytical method validation for equipment cleaning swab samples testing.

2. Your Dissolution by HPLC test procedures is deficient to ensure reliability of test results for the following reasons:

SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Pratik S Upadhyay, Steven A Brettler,		Prefit & Upachiyay Institutation Signed By Pha Is & Upachiyay -6 Date Signed: 05-25-2024 X	DATE ISSUED 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIO	DNS	PAGE 12 of 18 PAGES

	DEPARTMENT OF HEAL FOOD AND DRUG	TH AND HUMAN SEI G ADMINISTRATION	RVICES	
DISTRICT ADDRESS AND PHON	NE NUMBER	DATE(S		
Rockville, MI	vn Drive, Room 2032) 20857	FEI NU		
		301	0453141	
NAME AND TITLE OF INDIVIDUA		6000 JA 6600	11 (Proceeding) - 1627	
Mr. Pramod Ku	umar Singh, Head of ^{(b)(4)} Opera	tions - India STREET ADDRESS	and Africa	
	tories Limited	(FDF-3) Plot	Nos. 11, 12, 13, Phase II, Sector	
CITY, STATE, ZIP CODE, COUN		TYPE ESTABLISHMENT INSPE	CTED	
Pithampur, D: Pradesh, 454	istrict Dhar, Madhya 775 India	(b)(4) Drug Pro	ducts Manufacture	2
Tradesh, 494				
(b) (4) at finished produc b. In STP No.: (b) (4) there products at release Subsequently, u and report, you date: 21-Sep-20	ts at release and stability samples at FPPNSD302R-04 for testing e is no mention of the amount of d	amount of disso lution timepoint long term and a ^{(b)(4)} Table issolution media imepoints. This m and accelerate tion of analytica tocol and the re amount of dis	blution media to be s. This procedure is u ccelerated stability co ts ^{(b)(4)} mg, ^{(b)(4)} mg, and a to be procedure is used for ed stability conditions. al method validation (a port (FP-NSLDAD-D ssolution media to be	nditions. ^{(b) (4)} mg ^{(b) (4)} at ^(b) testing finished AMV) protocol S-M, Approval ^{(b) (4)}
analytical meth and report (MT Tablets ^{(b)(4)} mg, to validation an	od transfer (AMT) protocol (MTP/ TR/FDF-3/DP/20/047-00, Approva ^{(b)(4)} mg, ^{(b)(4)} mg, and ^{(b)(4)} mg d transfer of analytical test method	FDF-3/DP/20/04 l date: 27-Nov- ^{(b) (4)} I (for	47-00, Approval date: 2020) pertaining to observed similar defic ^{(b) (4)} Tablets ^{(b) (4)} mg, ^{(b) (4)}	11-Aug-2020), (*) (4) iencies relating mg, and (*) (4) mg
Furthermore, the timepoints for t during the proce			on profile testing that	vith dissolution was performed
				(b) (4)
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Pratik S Upadhyay, Investiga Steven A Brettler, Investiga		Pratit 6 Upadfyny Breddig Dan B 6 Upadfyny -6 Date figneri 65-36-2024 X	DATE ISSUED 6/26/2024
FORM ED 4 483 (00/09)	BEELINDIK EDITION ODEOL ETC TNG	PECTIONAL OBSER	VATIONS	PAGE 13 of 18 PAGES
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	DI LUTIONAL OBSER	VATIONS	

	TH AND HUMAN SERVICES
FOOD AND DRUG	G ADMINISTRATION DATE(S) OF INSPECTION
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*
Rockville, MD 20857	FEI NUMBER
1000001110, 112 20000	3010453141
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Mr. Pramod Kumar Singh, Head of ()(4) Opera	tions - India and Africa
FIRM NAME	STREET ADDRESS
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,
8.3 A Le 194-450 Kickshold Reserverse energie ou une derestation of the second seco	Pharma Zone, Phase II, Sector III
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Pithampur, District Dhar, Madhya	(b)(A) David
	(b)(4) Drug Products Manufacturer
Pradesh, 454775 India	(b)(4)
 B. Your Quality Unit failed to provide a written at "9"(4) "good tablets" from each container/pack after outside the acceptable range of weight according to AND CLEANING PROCEDURE FOR THE CONTENT OF THE PROCEDURE FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR	(b)(4) (d) (d) (d) (d)
 B. Your Quality Unit failed to provide a written at "good tablets" from each container/pack after outside the acceptable range of weight according to AND CLEANING PROCEDURE FOR TH (b)(4) " under section 6.3.7.4. There is van (b)(4) tablets) and the largest 	(b)(4) and documented scientific justification to only sample er at least (b)(4) tablet reject was identified to be to your firm's SOP-000464236 titled, "OPERATION HICKNESS SORTING MACHING – MAKE ariability in the batch sizes for the smallest (b)(4)

Specifically,

Your Quality Unit lacks an oversight on the integrity of data pertaining to packaging material testing. For example,

(b) (4) A. Your QC Analysts potentially falsified testing data pertaining to Chemical Analysis. Per your STP No.: PMPFL001-08, Effective date: 19-Aug-2021, section 4.1.1, it takes about to complete the analysis. On 25-Jun-2024, your QC Analyst ^{(b)(4)} samples relating to different batches post completion of weighing these ^{(b)(4)} samples relating to different batches post completion of weighing these ^{(b)(4)} A. Your QC Analysts potentially falsified testing data pertaining to identification test by he lost all samples relating to unrefer batches post completed for (4) out of (4) batches was found completed for (4) batches (6)(4) identification test by (4) test data revealed that QC

SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Pratik S Upadhyay, Steven A Brettler,		Pratit 6 Upadhyay Boctaggir - a 8, 9, Upadhyay - 6 Date Signet: 05-35-2034 X	date issued 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 14 of 18 PAGES

	TH AND HUMAN SERVICES G ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*
Rockville, MD 20857	FEINUMBER 3010453141
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	÷.
Mr. Pramod Kumar Singh, Head of ()(4) Opera	tions - India and Africa
FIRM NAME	STREET ADDRESS
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,
n 20 - Canada Sana ang kanang kana S	Pharma Zone, Phase II, Sector III
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Pithampur, District Dhar, Madhya Pradesh, 454775 India	(6)(4)Drug Products Manufacturer

Analysts that claimed to have completed the analysis were not present in the firm to conduct identification analyses per STP No.: PMPFL001-08, section 4.1.1. The details relating to raw test data worksheets and biometric/attendance log for QC Analysts are as follows:

			Ta	ble 4	
Sr. No.:	Batch No.:	Weight taken (Date/Timestamp)	Time required to complete analysis	Analysts Initial: Attendance Log for In/Out (Date/Time)	Result reported as Complies by Analyst (Date)
1	(b) (4,	16-Jan-2024 (b) (4)	About ^(b) (i.e. by (b) (4) (i.e. by (b) (4) (a) (4) (4) testing (4) testing (4) testing (5) (4) (4) testing (6) (4) (4) (5) (4) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5)	(b) (4), (b	0 ⁽⁶⁾ (0) (0) 16/Jan/2024
2 3		16-Jan-2024 (b) (4) 16-Jan-2024 (b) (4)			(b) (c) *Not initialed and dated
4		16-Jan-2024 ^{(b) (4)}			

* Analyst 6 stated that he completed the analysis on 16-Jan-2024.

Your Analysts (b)(6) provided no explanation about how they performed testing for four (4) out of batches for identification testing while per Analyst (b)(6) all (b)(4) samples were lost and none of it could be found. Thereby, it appeared that your Analysts potentially completed the raw data worksheet for the referenced batches (b)(4) by simply writing "Complies" followed by sign and date.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Pratik S Upadhyay, Steven A Brettler,		Pratit S Upachyay Biger By Biger By Date Bignet: 06-36-3034 X X	DATE ISSUED 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 15 of 18 PAGES

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*
Rockville, MD 20857	FEINUMBER 3010453141
Mr. Pramod Kumar Singh, Head of ^{(b)(4)} Op	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Mr. Pramod Kumar Singh, Head of (0)(4) Op FIRM NAME	STREET ADDRESS
Mr. Pramod Kumar Singh, Head of ()(4) Op FIRM NAME	
Mr. Pramod Kumar Singh, Head of ()(4) Op	STREET ADDRESS (FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,

B. On 24-Jun-2024, your Assistant Manager of QC deviated from procedure SOP-000565134, Titled: Good Quality Control Practices, Version: 38.0, section 6.9.1.23 relating to Good Documentation Practices (GDPs) by overwriting, and scrubbing the numbers by writing information on the approved controlled document in blue ink pen. This controlled document was titled "List for Packaging material Approved T.P. LIT", FORM -000564405, Signed and dated under Prepared By, Reviewed By, and Approved By on 01-Jun-2024. This document contained ^{(b)(4)} serial numbers pertaining to unique Material Code (M. Code) assigned to different materials. Per QC Manager, serial numbers are followed to locate T.P. LIT (Transparency Literature) and accordingly packaging material's "Printing" verification test is performed each time the material is received. However, "List for Packaging material Approved T.P. LIT" document contained incorrect information pertaining to Material Code being assigned to a different material and the same serial number was assigned to multiple materials. For ^{(b) (4)} and LIT example, serial number ^{(b)(4)} was assigned to two (2) different materials named LIT (b) (4) However, per "List for Packaging material MG TAB Approved T.P. LIT" serial number ^{(b) (4)} was assigned to material LIT only.

Furthermore, the evaluation of packaging material raw data worksheet revealed the information pertaining "Printing" test specification limit was pre-printed and your QC Analyst were simply required to write "Confirm". There is a potential for inadequacies in conducting this test due to the practices of simply writing "Confirm" on the worksheet based on the fact that two (2) different materials were assigned the same serial number and the transparency literature if would have been referred while conducting "Printing" test to by your QC Analyst this issue would have been identified and the test would not have confirmed to the specification limit.

OBSERVATION 5

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

Specifically,

SEE REVERSE OF THIS PAGE			Pratik S Upadhyay Investuger Date Signet: 06-36-2004 X	date issued 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIO	DNS	PAGE 16 of 18 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*			
Rockville, MD 20857	FEI NUMBER 3010453141			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Mr. Pramod Kumar Singh, Head of ()(4) Opera				
FIRM NAME	STREET ADDRESS			
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ,			
	Pharma Zone, Phase II, Sector III			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Pithampur, District Dhar, Madhya Pradesh, 454775 India	(6)(4) Drug Products Manufacturer			

A. Your Quality Unit failed to identify and investigate at least two (2) quality events relating to "Auditing Breached" documented on the audit trail for the (Equipment ID:

^{(b)(4)}) for ^{(b)(4)} audit trail review on ^{(b)(4)} as required for SOP-003059163 titled, "PROCEDURE FOR OPERATION AND CALIBRATION OF PARTICLE SIZE ANALYZER" under section 6.22 ^{(b)(4)} database review) and section 6.23 (Audit Trail Review), respectively.

B. Two (2) personnel of Quality Assurance (QA) for your firm appears to have "full" administration access to at least equipment/instruments within the Quality Control (QC) Laboratory with at least of the equipment/instruments with an audit trail.

PRODUCTION SYSTEM

OBSERVATION 6

Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of manufacturing and processing of the drug product.

Specifically,

Your Quality Unit failed to calculate and document the yield percentages of ^{(b)(4)} packaging batches for the U.S. Market. There are approximately ^{(b)(4)} batches for the U.S. Market for which the percent yields were not calculated, documented, and reviewed for any potential issues with the specific and separate packaging operation of each batch.

***DATES OF INSPECTION**

6/14/2024(Fri), 6/17/2024(Mon), 6/18/2024(Tue), 6/19/2024(Wed), 6/20/2024(Thu), 6/21/2024(Fri), 6/24/2024(Mon), 6/25/2024(Tue), 6/26/2024(Wed)

SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Pratik S Upadhyay, Steven A Brettler,		DATE ISSUED 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	PAGE 17 of 18 PAGES

	LTH AND HUMAN SERVICES UG ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
12420 Parklawn Drive, Room 2032	6/14/2024-6/26/2024*
Rockville, MD 20857	FEI NUMBER 3010453141
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Mr. Pramod Kumar Singh, Head of (*)(4)Oper	ations - India and Africa
FIRM NAME	STREET ADDRESS
Mylan Laboratories Limited	(FDF-3) Plot Nos. 11, 12, 13, Indore SEZ, Pharma Zone, Phase II, Sector III
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Pithampur, District Dhar, Madhya Pradesh, 454775 India	(b)(4) Drug Products Manufacturer
	•

APPEARS
THIS WAY ON
ORIGINAL

SEE REVERSE OF THIS PAGE			Inetit 5 Usethray Inetitigatin Signed By Pre 8 & Loadhyay-6 Date Egnet: 06-36-3004 X	DATE ISSUED 6/26/2024
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 18 of 18 PAGES